Mednet Logo
HomePediatric Hematology/OncologyQuestion

When using daratumumab in the setting of post-transplant red cell aplasia or post-transplant immune-mediated cytopenias, do you hold the drug for certain ANC parameters?

1 Answers
Mednet Member
Mednet Member
Pediatric Hematology/Oncology · CWRU School of Medicine

Typically, we do not hold until below ANC 500.

Register or Sign In to see full answer